Sign Out
Granules: L-Ornithine-L-Aspartate (Hepa-Merz) granules contain fructose. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
L-Ornithine-L-Aspartate (Hepa-Merz) granules contain 1.13g fructose per sachet (equivalent to 0.11 CEU). This should be taken into account in patients with diabetes mellitus.
L-Ornithine-L-Aspartate (Hepa-Merz) granules may be harmful to the teeth (caries) in long-term use.
Infusion: At high doses of L-Ornithine-L-Aspartate (Hepa-Merz) infusion concentrate, serum and urine urea levels should be monitored. If liver function is substantially impaired, the infusion rate must be adjusted to the individual patient in order to prevent nausea and vomiting.
Use in Children: No data are so far available on the use of the drug in children.
Effects on the ability to drive and use machines: Depending on the underlying disease, the ability to drive and operate machines may also be impaired on treatment with L-Ornithine-L-Aspartate.
